The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | NGS Vs PCR for EGFR genotyping in NSCLC
Hazel O’Sullivan, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, discusses whether PCR or next-generation sequencing (NGS) should be used to genotype EGFR in non-small cell lugn cancer (NSCLC) Due to a faster turnaround time, PCR is often used over next-generation sequencing to genotype EGFR per standard of care (SOC). However, previous reports have indicated 50% of EGFR exon 20 insertions and 30% of other uncommon EGFR mutations are missed with commonly used PCR assays.This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
